Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Water vs. IV: could a simple drink prevent kidney damage from CT dye?

NCT ID NCT07459413

Disease control Sponsor: Gaziosmanpasa Research and Education Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares drinking water to receiving IV fluids for preventing kidney injury caused by contrast dye used in CT scans. Researchers will enroll 198 emergency department patients with mild-to-moderate kidney disease. Participants will either drink water or get IV fluids before and after their scan, and their kidney function will be checked 48-72 hours later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Water (oral hydration)
What this could lead to
If successful, this could show that simply drinking water is as effective as IV fluids for protecting kidneys during CT scans, simplifying care.
What could go wrong
This is a small, early-stage trial (198 participants) and only tests a non-inferiority hypothesis. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 198 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years and older. * Patients with an estimated Glomerular Filtration Rate (eGFR) between 15-59 mL/min/1.73 m². * Patients undergoing contrast-enhanced computed tomography (CT) in the emergency department. * Patients who have provided written informed consent. Exclusion Criteria: * Pregnant women. * Patients with end-stage renal disease (ESRD) receiving dialysis or those with an eGFR \<15 mL/min/1.73 m². * Patients presenting with decompensated heart failure. * Patients with a known allergy to iodinated contrast media. * Patients with contrast media exposure within the last 72 hours. * Patients for whom oral intake is contraindicated or who cannot tolerate oral intake

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contrast-associated acute kidney injury Contrast-induced nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gaziosmanpasa Training and Research Hospital

    RECRUITING

    Istanbul, Gaziosmanpasa, 34255, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.